سعر تالتز 80مجم /مل 2026

Ixekizumab 80 mg/ml solution for subcutaneous injection (Eli Lilly), a humanized interleukin-17A antagonist monoclonal antibody.

• Moderate-to-severe plaque psoriasis in candidates for systemic therapy or phototherapy.Population: Patients 6 years and olderDailyMed (U.S. National Library of Medicine)
• Active psoriatic arthritis.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Active ankylosing spondylitis.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=1%): injection site reactions, upper respiratory tract infections, nausea and tinea infections.International label, same product · DailyMed (U.S. National Library of Medicine)

• Previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or any excipient.International label, same product · DailyMed (U.S. National Library of Medicine)

• Serious infections: discontinue until a serious infection resolves; evaluate for tuberculosis before starting.International label, same product · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity: discontinue immediately if a serious allergic reaction occurs.International label, same product · DailyMed (U.S. National Library of Medicine)
• Severe eczematous eruptions reported postmarketing.International label, same product · DailyMed (U.S. National Library of Medicine)

• Human data are insufficient to evaluate a drug-associated risk; human IgG crosses the placenta so ixekizumab may reach the fetus. A pregnancy exposure registry exists.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; ixekizumab was detected in milk of lactating monkeys.International label, same product · DailyMed (U.S. National Library of Medicine)